Hey, Rocky! … Watch Me Pull Hyperbole Out of my Hat

The financial press says, on Friday, the shorts got slaughtered.
Is that true, or just more hyperbole?
To find out, we’ll take a look at the active short in biotech XBI, and see if there was a ‘slaughter’, or something more constructive.
Biotech XBI, Daily
The last post inferred, ‘there’s no end in sight’ (not advice, not a recommendation).
Is that still true?

A present, we have a channel (with center-line) whose sections are a Fibonacci multiple.
If the channel is still in effect and the next session does not decisively break to the upside, then we can see price action is testing and validation that right side.
The good part or scary part depending on one’s perspective, XBI is validating the ‘supply’ side of the channel (where selling occurs).
Way down lower, is the ‘demand’ side … way down.
Stay Tuned
Charts by StockCharts
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
The Danger Point®, trade mark: No. 6,505,279


















